Previous close | 4.1100 |
Open | 4.2600 |
Bid | 4.3600 x N/A |
Ask | 4.4450 x N/A |
Day's range | 4.2600 - 4.2600 |
52-week range | 2.8400 - 8.9500 |
Volume | |
Avg. volume | 24 |
Market cap | 151.154M |
Beta (5Y monthly) | 1.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4500 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 36.71 |
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast, please use the followi
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024. The Achieve corporate presenta
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2023 Earnings Call Transcript March 28, 2024 Achieve Life Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2023 Earnings Conference Call […]